Award will enable researcher to bring lab discovery to clinical trial

April 03, 2007

LEXINGTON, Ky. (April 3, 2007) Dr. Jayakrishna Ambati's research into macular degeneration, which causes blindness among hundreds of thousands of people each year, has been heralded by the journal Science as one of the most exciting scientific breakthroughs of the year.

Now, because of a prestigious new national honor, the University of Kentucky researcher is getting the opportunity to take a recent discovery from the lab into clinical trials that may help patients successfully fight age-related macular degeneration.

Ambati is the first UK researcher ever to receive the Burroughs Wellcome Fund (BWF) Clinical Scientist Award in Translational Research. In fact, he is one of only 11 scientists in the nation to receive the award this year.

The award - which carries with it a grant of $750,000 - will allow Ambati and his team to fine-tune their discovery and develop a phase 1 clinical trial with patients.

"The number of people in the U.S. with macular degeneration is greater than that with all types of cancer combined," Ambati said. "Macular degeneration can lead to blindness, something that people fear even more than premature death.

With the help of the Burroughs Wellcome Fund, my colleagues and I are eager to advance new preventive and therapeutic strategies to hasten the day when blindness from macular degeneration is no longer inevitable. While it is extremely gratifying to be individually recognized with this prestigious award, it rightly belongs to my entire highly talented laboratory."

Ambati's work centers on accelerating the discovery of classes of compounds that suppress angiogenesis, or the growth of new blood vessels. Researchers are currently looking for therapies that will inhibit the growth of new blood vessels under the retina, which is the most debilitating type of macular degeneration, referred to as the "wet" form. Ambati already has discovered one new class of compounds to inhibit blood vessel growth and the funding will help him narrow down one or two lead candidates in this class to test clinically in patients with age-related macular degeneration.

"UK's ophthalmologists have transformed lab discoveries into innovative treatments for other conditions that threaten vision," Ambati said. "The biggest obstacle, however, is the cost of biomedical research. We are excited about the funding from the Burroughs Wellcome Fund, and will continue to seek additional opportunities to move our ideas forward so macular degeneration can be eradicated."

Ambati is engaged in the clinical practice of ophthalmology as well as in basic research. The foundation's award is for independent physician-scientists who are dedicated to translational research--the two-way transfer between laboratory research and patient treatment--and mentoring physician-scientist trainees.

"We hope these awards will lead to better understanding of the mechanisms of disease as well as new methods of diagnosing, treating and preventing disease," said BWF President Enriqueta C. Bond. "BWF is particularly interested in supporting physician-scientists who bring novel ideas and new approaches to translational research."

In 2003, Ambati and colleagues were responsible for discovering the first animal model of age-related macular degeneration. The model provides a method to study how and why humans develop this condition and provides a platform on which to develop and validate new therapeutic strategies. Ambati's animal model closely resembles the anatomical appearance, biochemical composition, and functional disruption of macular degeneration in humans. More recently, Ambati and his brother, Dr. Balamurali Ambati, of the Medical College of Georgia, jointly published a paper in the journal Nature detailing their discovery that a protein known as sVEGFR-1 is singularly responsible for warding off blood vessel growth in the cornea. The article "Corneal Avascularity is due to soluble VEGF receptor-1" appeared in the Oct. 26, 2006 print edition and online version of Nature, and was cited by Science as one of the breakthroughs of 2006.

Ambati is associate professor and vice-chair in the UK College of Medicine Department of Ophthalmology and Visual Sciences and is the Dr. E. Vernon Smith and Eloise C. Smith Endowed Chair in Macular Degeneration.
-end-
To make an appointment for age-related macular degeneration evaluation or treatment, call the UK Department of Ophthalmology at (859) 323-5867. UK HealthCare's ophthalmologists are committed to patient care and can provide information about enrolling in clinical trials for this condition.

In striving to become a Top 20 public research institution, the University of Kentucky is a catalyst for a new Commonwealth - a Kentucky that is healthier, better educated, and positioned to compete in a global and changing economy. For more information about UK's efforts to become a Top 20 university, please go to http://www.uky.edu/OPBPA/Top20.html.

University of Kentucky

Related Blood Vessels Articles from Brightsurf:

Biofriendly protocells pump up blood vessels
In a new study published today in Nature Chemistry, Professor Stephen Mann and Dr Mei Li from Bristol's School of Chemistry, together with Associate Professor Jianbo Liu and colleagues at Hunan University and Central South University in China, prepared synthetic protocells coated in red blood cell fragments for use as nitric oxide generating bio-bots within blood vessels.

Specific and rapid expansion of blood vessels
Upon a heart infarct or stroke, rapid restoration of blood flow, and oxygen delivery to the hypo perfused regions is of eminent importance to prevent further damage to heart or brain.

Flexible and biodegradable electronic blood vessels
Researchers in China and Switzerland have developed electronic blood vessels that can be actively tuned to address subtle changes in the body after implantation.

Lumpy proteins stiffen blood vessels of the brain
Deposits of a protein called ''Medin'', which manifest in virtually all older adults, reduce the elasticity of blood vessels during aging and hence may be a risk factor for vascular dementia.

Cancer cells take over blood vessels to spread
In laboratory studies, Johns Hopkins Kimmel Cancer Center and Johns Hopkins University researchers observed a key step in how cancer cells may spread from a primary tumor to a distant site within the body, a process known as metastasis.

Novel function of platelets in tumor blood vessels found
Scientists at Uppsala University have discovered a hitherto unknown function of blood platelets in cancer.

Blood vessels can make you fat, and yet fit
IBS scientists have reported Angiopoietin-2 (Angpt2) as a key driver that inhibits the accumulation of potbellies by enabling the proper transport of fatty acid into general circulation in blood vessels, thus preventing insulin resistance.

Brothers in arms: The brain and its blood vessels
The brain and its surrounding blood vessels exist in a close relationship.

Feeling the pressure: How blood vessels sense their environment
Researchers from the University of Tsukuba discovered that Thbs1 is a key extracellular mediator of mechanotransduction upon mechanical stress.

Human textiles to repair blood vessels
As the leading cause of mortality worldwide, cardiovascular diseases claim over 17 million lives each year, according to World Health Organization estimates.

Read More: Blood Vessels News and Blood Vessels Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.